NASDAQ:HTBX - Heat Biologics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 191.12 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.87
▲ +0.17 (2.54%)
1 month | 3 months | 12 months
Get New Heat Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HTBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HTBX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$20.00
▲ +191.12% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Heat Biologics in the last 3 months. The average price target is $20.00, with a high forecast of $40.00 and a low forecast of $4.00. The average price target represents a 191.12% upside from the last price of $6.87.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Heat Biologics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2021Cantor FitzgeraldInitiated CoverageOverweight$22.00High
i
Rating by K. Kluska at Cantor Fitzgerald
2/9/2021Alliance Global PartnersBoost Price TargetPositive ➝ Buy$5.00 ➝ $40.00Low
i
2/9/2021Maxim GroupReiterated RatingBuy$14.00Low
i
12/24/2020B. RileyReiterated RatingBuyN/A
i
Rating by M. Mamtani at B. Riley
12/3/2020B. RileyReiterated RatingBuy$4.00Low
i
10/14/2020B. RileyReiterated RatingBuyMedium
i
Rating by J. Zelin at B. Riley
10/14/2020B. RileyInitiated CoverageBuy$4.00 ➝ $4.00Low
i
6/19/2020Maxim GroupInitiated CoverageBuy$2.00Low
i
Rating by Jason McCarthy at Maxim Group
5/15/2020Maxim GroupInitiated CoverageBuy$2.00Low
i
Rating by Jason McCarthy at Maxim Group
4/1/2020Maxim GroupReiterated RatingBuy$2.00Medium
i
3/5/2020Maxim GroupBoost Price Target$1.00 ➝ $2.00High
i
3/3/2020Maxim GroupReiterated RatingBuy$1.00High
i
2/6/2020Maxim GroupInitiated CoverageBuyHigh
i
7/29/2019Brookline Capital ManagementInitiated CoverageBuy$8.00 ➝ $8.00High
i
Rating by K. Raja at Brookline Capital Management
5/17/2019Alliance Global PartnersSet Price TargetBuy$6.00Medium
i
Rating by James Molloy at Alliance Global Partners
11/16/2018HC WainwrightSet Price TargetBuy$6.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/1/2018Brookline Capital ManagementReiterated RatingBuyLow
i
Rating by K. Raja at Brookline Capital Management
7/9/2018Eurobank EFGInitiated CoverageBuy$11.00High
i
Rating by James Molloy at Eurobank EFG
6/26/2018HC WainwrightInitiated CoverageBuy$6.00High
i
Rating by J. Pantginis at HC Wainwright
9/12/2017Griffin SecuritiesInitiated CoverageBuy$22.50High
i
Rating by K. Markey at Griffin Securities
7/4/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
5/14/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Mark Jordan at Noble Financial
4/6/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Mark Jordan at Noble Financial
3/23/2017Noble FinancialReiterated RatingBuyHigh
i
3/13/2017Noble FinancialReiterated RatingBuyHigh
i
12/8/2016Roth CapitalSet Price TargetBuy$20.00N/A
i
Rating by Joseph Pantginis at Roth Capital
12/1/2016Roth CapitalSet Price TargetBuy$27.50 ➝ $20.00N/A
i
Rating by Joseph Pantginis at Roth Capital
9/15/2016Roth CapitalReiterated RatingBuy$27.50N/A
i
Rating by Joseph Pantginis at Roth Capital
8/17/2016Noble FinancialReiterated RatingBuy$80.00N/A
i
8/17/2016Roth CapitalReiterated RatingBuy$27.50N/A
i
Rating by Joseph Pantginis at Roth Capital
6/20/2016Roth CapitalInitiated CoverageBuy$27.50N/A
i
Rating by J. Pantginis at Roth Capital
(Data available from 4/14/2016 forward)
Heat Biologics logo
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $6.87
$6.72
$6.87

50 Day Range

MA: $7.96
$6.92
$9.20

52 Week Range

Now: $6.87
$3.50
$30.10

Volume

3,209 shs

Average Volume

2,278,642 shs

Market Capitalization

$174.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Heat Biologics?

The following Wall Street sell-side analysts have issued reports on Heat Biologics in the last year: Alliance Global Partners, B. Riley, Cantor Fitzgerald, and Maxim Group.
View the latest analyst ratings for HTBX.

What is the current price target for Heat Biologics?

4 Wall Street analysts have set twelve-month price targets for Heat Biologics in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 191.1%. Alliance Global Partners has the highest price target set, predicting HTBX will reach $40.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $4.00 for Heat Biologics in the next year.
View the latest price targets for HTBX.

What is the current consensus analyst rating for Heat Biologics?

Heat Biologics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HTBX will outperform the market and that investors should add to their positions of Heat Biologics.
View the latest ratings for HTBX.

What other companies compete with Heat Biologics?

How do I contact Heat Biologics' investor relations team?

Heat Biologics' physical mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company's listed phone number is 919-240-7133 and its investor relations email address is [email protected] The official website for Heat Biologics is www.heatbio.com.